Biocrates Newsletter Issue #3

You can’t see this email? View it in your browser.
Newsletter Issue #3
2014
Alzheimer Newsletter v3
Metabolic Phenotyping: Breakthrough in Neuroscience

First published report of a blood-based biomarker panel with very high accuracy for detecting preclinical Alzheimer's disease (Mapstone et al., Nature Medicine, 2014).
 --
View Abstract
 -- View
Press Release

Metabolomics is emerging as a powerful new technologoy platform that will play a key role in the identification of CNS biomarkers. These biomarkers can be used to identify individual at risk at the preclinical stage, provide better diagnostic and surrogate markers of disease and its progression and allow clinicians to provide a more accurate and early prognosis.

In this newsletter edition we will outline some important neurological studies (performed by Biocrates Kits), which show metabolomics’ full potential in the field of neuroscience.

Mapstone TitelMapstone et al., Nature Medicine, 2014
Blood test predicts Alzheimer's

Discovery and validation of a set of 10 lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer’s disease within a 2–3 year timeframe with over 90% accuracy.

This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neuro-degeneration of preclinical Alzheimer’s disease.

Grimm TitelGrimm et al., J Chromatogr A., 2011

Alzheimer's and Nutrition:
Influence of food intake

Grimm et al., 2011, suggest that specific diet might be beneficial in Alzheimer's disease.
He Titel v2.gifHe et al., Transl. Psychiatry, 2012
Diagnosis of Schizophrenia
The study from He et al. illustrated that the metabolic deviations detected in plasma may serve as potential biomarkers to aid diagnosis of schizophrenia (ornithine, arginine, glutamine, histidine, PC ae C38:6).

Mandal Titel v2

Mandal et al., Genome Medicine, 2012

Analysis of Metabolites in CSF
The study from Mandal et al. shows that Biocrates' Metabolic Phenotyping Kits can be successfully used to perform quantitative analyses of human cerebrospinal fluid.
About Biocrates
BIOCRATES Life Sciences AG offers unique solutions for targeted, quantitative and quality-controlled metabolic phenotyping  The spectrometry-based assays are marked by unprecedented accuracy and precision, thus providing a comprehensive and predictive understanding of phenotypes and metabolic pathways.
Contact
BIOCRATES Life Sciences AG
Eduard-Bodem-Gasse 8, 6020 Innsbruck
+43 512 579823
+43 512 579823 329
office@biocrates.com
Please click here to unsubscribe.
This email was sent by: BIOCRATES Life Sciences AG, Eduard-Bodem-Gasse 8, 6020 Innsbruck martina.klocker@biocrates.com
Phone +43.512.579 823, Fax +43.512.579 823–329, FN 220414 p LG Innsbruck,
Powered by AcyMailing